These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32383642)

  • 1. Interactions of sugammadex with various anticoagulants
.
    Kruithof AC; Kluft C; de Kam PJ; Laterveer GH; Moerland M; Burggraaf J
    Int J Clin Pharmacol Ther; 2020 Jul; 58(7):395-403. PubMed ID: 32383642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.
    De Kam PJ; Grobara P; Prohn M; Höppener F; Kluft C; Burggraaf J; Langdon RB; Peeters P
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):227-36. PubMed ID: 24447651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact.
    Dirkmann D; Britten MW; Pauling H; Weidle J; Volbracht L; Görlinger K; Peters J
    Anesthesiology; 2016 Jun; 124(6):1277-85. PubMed ID: 26950705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PK-PD model-based assessment of sugammadex effects on coagulation parameters.
    Bosch R; van Lierop MJ; de Kam PJ; Kruithof AC; Burggraaf J; de Greef R; Visser SA; Johnson-Levonas AO; Kleijn HJ
    Eur J Pharm Sci; 2016 Mar; 84():9-17. PubMed ID: 26747019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixing Studies in Patients With Prolonged Activated Partial Thromboplastin Time or Prothrombin Time.
    Benzon HT; Park M; McCarthy RJ; Kendall MC; Lindholm PF
    Anesth Analg; 2019 Jun; 128(6):1089-1096. PubMed ID: 31094773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
    De Kam PJ; Kruithof AC; van Lierop MJ; Moerland M; Dennie J; Troyer MD; Langdon RB; Gutstein DE; Burggraaf J; El Galta R
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):631-41. PubMed ID: 24800921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Acute Need Inspiration: Autoneutralization of Lupus Anticoagulants in Affected Prothrombin Times (PT) and Activated Partial Thromboplastin Times (APTT).
    Gosselin RC
    Methods Mol Biol; 2023; 2663():289-295. PubMed ID: 37204718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs.
    Fadraersada J; Alva-Gallegos R; Skořepa P; Musil F; Javorská L; Matoušová K; Krčmová LK; Paclíková M; Carazo A; Blaha V; Mladěnka P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4461-4470. PubMed ID: 38112731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mode of action of sugammadex on coagulation.
    Kruithof AC; Kluft C; de Kam PJ; Laterveer RH; Moerland M; Burggraaf J
    Int J Clin Pharmacol Ther; 2021 Feb; 59(2):89-98. PubMed ID: 33155541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
    Cammu G; De Kam PJ; Demeyer I; Decoopman M; Peeters PA; Smeets JM; Foubert L
    Br J Anaesth; 2008 Mar; 100(3):373-9. PubMed ID: 18238834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.